glp-1 manufacturing news today New oral drugs could offer more options for weight loss What's next for GLP-1s? —

Yadav, S., Sharma, S., Sharma, K

Extra caution is advised in people with: A history of pancreatitis Severe acidity or gastroparesis (very slow stomach emptying) Known gallstones or gallbladder disease Advanced kidney disease Significant diabetic eye disease (retinopathy) A very low BMI or a history of eating disorders Pregnancy, plans to become pregnant, or breastfeeding, since some GLP-1 medicines stay in the body for several weeks after stopping Significant depression, who should be monitored carefully Upcoming surgery, endoscopy, or a procedure needing anaesthesia or sedation, since delayed stomach emptying can raise aspiration risk and temporary stopping may be advised How GLP-1 side effects usually progress: a typical timeline Every person is different, but clinical practice and studies suggest a rough pattern [6]: First 2 to 6 weeks: nausea, early fullness, and constipation are most common

GHK-Cu binds to copper with high affinity

Researchers posit that when Melanotan I activates MC1R, cAMP is produced, and it activates microphthalmia transcription factor (MITF) expression, which induces the expression of enzymes for eumelanin production

James Kilgour, MD